Drug asset scouting · For biotech teams and investors
Find the shelved drug worth a second look.
Tell Hive what science you need and what you can spend on the next experiment. Get a sourced decision report: what qualifies, what remains unknown, and what to do next.
No card to create a brief. A focused investigation is $2,500 once, after scope and start date are agreed. No subscription required for the investigation.
One question. A defined piece of work.
A smaller first commitment.
The evidence rule
An interesting drug is not yet an opportunity.
Hive checks identity and current evidence before assessment. Six mandatory tests then decide whether an asset qualifies. Only qualifying assets are ranked. Unknown facts stay in research.
Missing ownership, an old status page, or an unaffordable experiment cannot be offset by an attractive score.
See the inputs and the six tests →Know what you are buying
Research that can tell you to stop.
The example report is fictional and labeled throughout. It shows an empty shortlist and a useful next decision. It is not a customer result or a claim that any drug is available.
Read the exampleUseful before you buy
Check the assumptions yourself.
Start with the decision you need to make.
Creating a brief does not start paid research or authorize contact with an asset owner.